Research
Hormonal
In humans, adipose tissue RBP4 expression is positively correlated with GLUT4 expression, whereas in rodents, they are inversely correlated, indicating a fundamental species difference in RBP4 regulation.
The biological link between glucose uptake (GLUT4) and RBP4 production is different in humans than in mice. This highlights why animal studies cannot always be directly translated to human obesity treatments.
GoodRefutesHIGH confidence
RBP4 was positively correlated with GLUT4 expression in adipose tissue, independent of any obesity-associated variable... These findings suggest a role of adipose glucose uptake/GLUT4 in the regulation of human RBP4, but profound differences exist between rodents and humans.
Why this rating
Robust statistical correlation (r=0.72) in a large human cohort.
Source
Retinol-Binding Protein 4 in Human Obesity
Jürgen Janke et al. · Diabetes · 2006
DOI 10.2337/db06-0616
cross_sectional · n=74Cited 353×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- In human postmenopausal women, circulating Retinol-Binding Protein 4 (RBP4) levels do not increase with obesity and are not correlated with insulin resistance, contradicting the rodent model where adipose RBP4 drives systemic insulin resistance.Good
- A 5% weight loss in obese women significantly improves the HOMA index of insulin sensitivity, but this improvement occurs without a significant change in circulating RBP4 levels.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →